Respiratory
Obstructive airway diseases, interstitial lung disorders, pulmonary hypertension, and chronic respiratory illnesses.
Core & active disease programs
Asthma
$107.9B attributable cost
78 assets · 1 indication
Chronic Obstructive Pulmonary Disease
$61.4B attributable cost
63 assets · 1 indication
Idiopathic Pulmonary Fibrosis
$6.5B+ attributable cost
$3.3B$+ drug spend
8 assets · 2 indications
Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis
Market size not yet sourced
0 assets · 0 indications
Provisional & emerging programs (9)Early clinical pipeline & single-asset indications
Pulmonary Arterial Hypertension
Pulmonary Hypertension Associated with Interstitial Lung Disease
Cystic Fibrosis
Allergic Bronchopulmonary Aspergillosis
Non-Cystic Fibrosis Bronchiectasis
Persistent Pulmonary Hypertension of the Newborn
Pulmonary Hypertension due to Left Heart Disease
Pulmonary Alveolar Proteinosis
Pulmonary Hypertension